Essential Thrombocythaemia research hub

A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia

This study looks at a new drug, STP938, for essential thrombocythaemia (ET) in adults where current treatment isn't working. It aims to see if STP938 safely lowers high platelet counts. Participants take the drug daily for up to a year, with regular check-ups.